ILA
ISLAND PHA FPO [ILA]
Healthcare · ASX Small Cap
$0.3650 +0.0%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical70
Catalyst50
Sentiment50
Fundamental34
Momentum67
Risk Gate42
Get alerts when ILA's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Stochastic is deep in oversold territory — bounce conditions forming
- Drifting lower — down 3.9% over the last 5 days
- Beating the Small Ords index — relative strength of 1.10, so it's outpacing the pack
- Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
- Trading above the 200-day average — the long-term trend is on your side
- Adequate cash runway (7 quarters)
- Very high P/S ratio (1715.8x)
- Revenue in sharp decline (-58%)
- EPS estimates revised downward (-10pts)
- Capital raise activity (1 events)
- CANSLIM S: Tight float (46%)
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 64% over the past year (excluding last month)
- The bigger volume days are the up days — volume-weighted momentum is positive (1.42%/day)
- Altman Z-Score distress zone (1.76 < 1.81, low-confidence approx)
- RBA hiking (-3pts)
- Dilution risk: technical breakout with recent capital raise
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -58% — the top line is shrinking
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about ILA
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Cleansing Notice
NONE Application for quotation of securities - ILA
MEDIUM Antiviral pipeline expansion through strategic collaboration
MEDIUM US Government collaboration for Galidesivir development
NEGATIVE Trading Halt
Recent ASX Announcements
| 2026-03-22 | Cleansing Notice |
| 2026-03-22 | Application for quotation of securities - ILA |
| 2026-03-08 | Antiviral pipeline expansion through strategic collaboration PRICE SENSITIVE |
| 2026-03-03 | US Government collaboration for Galidesivir development PRICE SENSITIVE |
| 2026-03-01 | Trading Halt PRICE SENSITIVE |
Key Metrics
$107.8M
Market Cap
387K
Avg Volume
0.7x
Vol Ratio
$0.12 — $0.63
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-130.3%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 46% |
| L | Leader vs Laggard | laggard | RS: -3 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #113 of 117 · Sector avg: 46
View all Healthcare signals →Track ILA and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required